GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 10, 2024, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs). The filing covers transactions executed on October 9, 2024, on the London Stock Exchange (XLON).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share acquisition transactions under the Company's Share Reward Plan.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: GBP 14.5185 per share.
- Total Volume Reported: 128 Ordinary Shares across eight executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine equity compensation acquisitions by senior leadership.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Executives Involved:
- Emma Walmsley (CEO): 16 shares.
- Julie Brown (CFO): 18 shares.
- James Ford (SVP, Legal): 16 shares.
- Sally Jackson (SVP, Communications): 16 shares.
- David Redfern (President, Corporate Development): 16 shares.
- Regis Simard (President, Global Supply Chain): 18 shares.
- Philip Thomson (President, Global Affairs): 18 shares.
- Deborah Waterhouse (CEO, ViiV Healthcare): 18 shares.
- Victoria Whyte (Company Secretary): 16 shares.
- Market Context: Transactions occurred at a uniform price of GBP 14.5185 on the London Stock Exchange.